Literature DB >> 9252849

A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis.

A Floreani1, F Zappala, W Fries, R Naccarato, M Plebani, A D'Angelo, M Chiaramonte.   

Abstract

We carried out a 3-year pilot study of 59 consecutive women with osteoporosis of primary biliary cirrhosis (PBC), allocating them to two groups according to the severity of bone demineralization assessed by means of dual-photon absorptiometry (DPA) of the lumbar spine, Group A (36 patients; bone mineral density [BMD] > 0.800 g/cm2) received no treatment; group B (23 patients; BMD < 0.800 g/cm2) was treated as follows: oral 1,25-dihydroxyvitamin D (0.5 microgram twice a day for 5 days) followed by a 1-month course with oral calcium carbonate (1,500 mg/day) +carbocalcitonin (40 UMRC intramuscularly three times weekly). This treatment was repeated every 3 months. The following parameters were assessed at baseline and every 12 months: DPA, serum and urinary minerals, serum parathyroid hormone (PTH), osteocalcin (BGP), 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D. During follow-up, 11 initially untreated patients whose BMD dropped below 0.800 g/cm2 were switched to the treatment group (8 after 12 months and 3 after 24 months). No significant changes were observed in either group for PTH, BGP, or vitamin D metabolites. Comparing patients who were always treated, those who were never treated, and those who switched to the treatment group (ever treated) in this 36-month period, the percentage of annual bone loss in the never-treated patients was significantly less (p < 0.002) than in the ever-treated patients, suggesting the presence of two subgroups in PBC patients; one with rapid bone loss and the other with slow bone loss. Moreover, in the ever-treated patients, ADFR (activate, depress, free, repeat) therapy resulted in an improvement in BMD (p < 0.05 compared with the value before therapy). We conclude that ADFR therapy is effective in the treatment of patients with PBC with severe osteodystrophy, despite no change in osteoblastic activity, although controlled, randomized studies are in order to confirm our data.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252849     DOI: 10.1097/00004836-199706000-00012

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  12 in total

1.  Guidelines on the management of osteoporosis associated with chronic liver disease.

Authors:  Jane D Collier; M Ninkovic; J E Compston
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 2.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

Review 3.  Osteopenia and osteoporosis in gastrointestinal diseases: diagnosis and treatment.

Authors:  J C Southerland; J F Valentine
Journal:  Curr Gastroenterol Rep       Date:  2001-10

Review 4.  Bone disorders in chronic liver diseases.

Authors:  Bruce A Luxon
Journal:  Curr Gastroenterol Rep       Date:  2011-02

5.  Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin.

Authors:  Robert H Boone; Angela M Cheung; Larisa M Girlan; E Jenny Heathcote
Journal:  Dig Dis Sci       Date:  2006-06       Impact factor: 3.199

Review 6.  Metabolic bone disease in patients with liver disease.

Authors:  Elizabeth Carey; Vijayan Balan
Journal:  Curr Gastroenterol Rep       Date:  2003-02

7.  Hepatic osteodystrophy in rats results mainly from portasystemic shunting.

Authors:  S W van der Merwe; J B van den Bogaerde; C Goosen; F F Maree; R J Milner; C M Schnitzler; A Biscardi; J M Mesquita; G Engelbrecht; D Kahn; J Fevery
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

Review 8.  Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications.

Authors:  Inaam A Nakchbandi
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

Review 9.  Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective.

Authors:  Renée M Marchioni Beery; Haleh Vaziri; Faripour Forouhar
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

Review 10.  Diagnosis and Management of Cirrhosis-Related Osteoporosis.

Authors:  Lívia Alves Amaral Santos; Fernando Gomes Romeiro
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.